Category Archives: Patent

Patent

The Politics of Patent Citations: Are Some Scholars More Equal than Others?


Last week, I was in for a bit of a shock! Spotted this piece on SSRN that touts the idea of an “investment protection regime” for new inventions. I’d mooted the very same idea (an investment protection regime for inventions) in my PhD thesis more than 8 years ago. This was later published (around 6 years ago) in the Journal of World IP,  as below: Shamnad Basheer, “The Invention of an Investment Incentive for Pharmaceutical Innovation”, 15 Journal of World…


Read More »
Patent

The 2018 Patent Agent Examination – Discrepancies and Some Fundamental Issues


We’re pleased to bring to you a guest post highlighting the discrepancies in this year’s Patent Agent Examination that was held last month on October 28. The post also raises a few fundamental and larger issues afflicting this exam. The author of this post wishes to remain anonymous. Our earlier posts discussing the concerns regarding the conduct and nature of this exam can be viewed here. The 2018 Patent Agent Examination – Discrepancies and Some Fundamental Issues Anonymous The Indian…


Read More »
Competition Law Patent Unfair Competition

US Court Grants Federal Trade Commissions Motion: Qualcomm Must License Any Willing Company, Including Rival Chip Makers


This is a monumental development: Judge Lucy H. Koh of the  Northern District of California has held that Qualcomm must license any willing licensee – this includes rival chipmakers, such as MediaTek or Intel or any other player.  This is huge: Qualcomm admittedly had never licensed any of its competitors.   Hence the decision may be read to hold that Qualcomm is in breach of its FRAND commitments. In my view, this judgement is also valuable from another perspective: Whether chipsets can…


Read More »
Patent

A Disgruntled Law Professor’s Open Letter to the US Supreme Court!


We’re pleased to bring you an unconventional post. A hilarious hard hitting letter penned by Prof. Glynn S. Lunney, Jr. to the US Supreme Court, taking issue with the uncertainty unleashed thanks to the doctrine of equivalents, as elucidated in Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co. This letter is likely to resonate with many of us who’ve been at the receiving end of court decisions that may be difficult to understand, much less teach. Professor Lunney is an…


Read More »
Overlaps in IP Patent

India’s IPR Regime Looks to Hi-Tech to Improve Administration – From Video Conferencing to AI and Blockchain


The IPR administrative offices form the backbone of the legal system of India’s IP regimes. The efficacy of the law depends, to a large extent, on how these offices manage their administrative tasks, which includes substantive evaluation of claims over IP, as well as tasks of effectively maintaining registries and public records. We have written, in the past, about many worrying aspects of their administration, such as non-transparent functioning of the Copyright Office, or the skewed incentives system within the…


Read More »
Patent

Bombay HC Addresses Ambiguity in the Patent Agent Examination


The Bombay HC recently delivered an order dealing with certain objections raised against the Patent Agent Examination, 2016. In their decision, they interpreted the Supreme Court’s decision in Kanpur University v. Samir Gupta (“Kanpur University”). This post examines the questions which arise due to the Court’s interpretation and application of this decision. The Question in Issue The Petitioner (a candidate who appeared for the said Examination) raised contentions regarding the answer options of a multiple choice question in the Examination…


Read More »
Drug Regulation Patent

IPO Grants Patent to Brodalumab


Last week, our IPO granted a patent to Amgen covering the drug Broadlumab.  Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases including psoriasis  In the United States, Broadlumab is known as Siliq and in Europe it is Kyntheum. The application for Broadalumab was filed as a PCT application – PCT/US2007/021174 (click here to see the page on WIPO – Patentscope) and was accorded application number: 2350/CHENP/2007. One can see the entire file on this link – https://www.quickcompany.in/patents/il-17-receiptor-a-antigen-binding-proteins Sandeep Rathod –…


Read More »
Copyright Overlaps in IP Patent Trademark

Obscenity and Morality under IP Law


  Obscenity under  the Indian Penal Code (“IPC”) is a relic of India’s colonial past. Though the need for such a provision is often subject to debate, it is indisputable that the judiciary’s interpretation of this provision has been often been anachronistic in past instances. The judiciary has, no doubt, evolved from the infamous Hicklin Test (tendency of the impugned material to deprave and corrupt those whose minds are open to such immoral influences) to the contemporary community standards (testing the impugned material against contemporary…


Read More »
Patent

Deconstructing the FRAND Regime vis-à-vis Recourse to Injunctive Relief


We’re pleased to bring to you a guest post by Subhajeet Roy. Subhajeet is a recent graduate of Tamil Nadu National Law School, Tiruchirappalli. Deconstructing the FRAND Regime vis-à-vis Recourse to Injunctive Relief Subhajeet Roy Background Before one gets into the question of availability of injunctive relief in disputes related to Standard Essential Patents (SEPs), a quick recap of some important terms would be helpful. SEPs are those patents that must be used in order to comply with a said…


Read More »
Drug Regulation Patent

Standing Against XTANDI: An E-mail Campaign to Ensure Accessibility to Cancer Wonder-Drug


In their latest efforts to stop the University of California, Los Angeles (UCLA) from pursuing a patent for Xtandi, the Universities Allied for Essential Medicines (UAEM) is sending an e-mail petition to Janet Napolitano, the President of University of California. This attempt comes after UAEM made a representation before the Regents of the University of California for a third time, demanding that Xtandi be made more accessible in India. Xtandi has an eventful if not long history of controversies in…


Read More »